ArticleOncology letters2017

Therapeutic response to a novel enzyme-targeting radiosensitization treatment (KORTUC II) for residual lesions in patients with stage IV primary breast cancer, following induction chemotherapy with epirubicin and cyclophosphamide or taxane.

Nobutaka Aoyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.